The company said the discontinuation was due to several reasons,” Reuters news service reported, “including limited interest ...

Alicia and Jon Langenhop's three children were each diagnosed with a rare disorder. A clinical trial was "a no-brainer." ...

The mood at the annual meeting of the American Society of Cell and Gene Therapy isn’t amazing. The biotech market has been ...

Gene therapy is at the cutting edge of medicine, with exciting new products being developed and used to treat a wide variety ...

Healthcare providers are exploring ways to reduce patient travel through a growing trend of expanding sites of administration ...

Explore ClearPoint Neuro's Q1 2025 performance, with 11% revenue growth, strategic investments, and strong biopharma partnerships.

GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec.

An interview with ASGCT's CEO and president Identifies the meeting's themes including scientific advances, new technologies, and funding constraints.

From connectors and containers to plasmids and platforms, companies work to get these treatments to patients faster and more ...

Two research articles published in Nature Genetics shed new light on the cellular complexity of glioblastoma, the most ...

Researchers at the Paul Scherrer Institute PSI have developed an AI that could open up a new, cost-effective approach to ...